1.Risk factors of sexual dysfunction in aged men in Beijing : a multicenter community-based cross-sectional survey
Jian SONG ; Qiang SHAO ; Shaopeng SUN ; Ye TIAN ; Yanqun NA
Chinese Journal of Urology 2012;33(4):300-304
Objective To investigate the prevalence of sexual dysfunction in aged men and associated risk factors in Beijing. Methods A cross-sectional study was performed in communities of Beijing involved 1656 men aged over 50 years.The International Index of Erectile Function-5 (IIEF-5),Brief Male Sexual Function Inventory for Urology ( O'Leary 1995 ) and the International Prostate Symptom Score (IPSS)questionnaires was recorded.The body mass index (BMI),prostate size was measured.The survey was conducted to make sure if the patients had diabetes,high blood pressure,hyperlipidemia,cerebrovascular history,and smoking and drinking situation.Pearson's X2 test and unconditional logistic regression were used to investigate the factors associated with sexual dysfunction. Results 1644 subjects were enrolled.The incidence of ED,reduction of sexual desire and defective ejaculation was 90.45%,60.04% and 38.81% respectively,and significantly different according to age ( P < O.05 ). Age was positively correlated with ED (3 =0.12,P<0.05),reduction of sexual desire (β =0.10,P<0.05) and defective ejaculation (β =0.10,P < 0.05 ) ; ED was significantly associated with BMI (β =0.07,P < 0.05 ).Hypertension and prostate size were risk factors for reduction of sexual desire and defective ejaculation; There was correlation between drinking and defective ejaculation ( β =- O.31,P < 0.05 ). Conelusions Compared with high prevalence of ED and lower sexual desire,the incidence of defective ejaculation were lower; this may reflect the sexual activities of aged male were more active compared with the less success of really erection.The prevalence of ED,reduction of sexual desire or defective ejaculation increased with age.BMI was the risk factor for ED.Enlarged prostate and hypertension was associated with reduction of sexual desire,and drinking was the risk factor for defective ejaculation.
2.Clinical Study of Yinao Capsules for Neurasthenia
Xiaoming LAI ; Shaopeng TIAN ; Huichen ZHANG ; Keer HUANG
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(04):-
Objective To evaluate the clinical effect and safety of Yinao Capsul es for neurasthenia with the syndrome of liver-kidney deficiency and Qi-yin de ficiency. Methods A multi-center,randomized,single-blind and positive drug p arallel controlled trial was adopted. Three hundred and forty-two cases in the treatment group were treated with Yinao Capsules,and 111 cases in the control g roup were treated with Naolinsu Capsules. Results Yinao Capsules had a total eff ective rate of 93.6 %and the markedly effective rate of 52.1 %. Compared with Naolinsu Capsules,Yinao Capsules showed a better clinical effect (P
3.Silencing of PSMA by RNAi influences biological behavior of prostate cancer cell line LNCaP
Kaiyuan CAO ; Tian ZHANG ; Lin XU ; Guangqing YUAN ; Xiaodong TIAN ; Xiaorong HUANG ; Shaopeng QIU
Chinese Journal of Pathophysiology 2000;0(10):-
AIM:To study the blocking effect of shRNA on the expression of PSMA gene in LNCaP cell line by using shRNA eukaryotic expression vector.METHODS:Three pairs of DNA templates coding shRNA,synthesized against PSMA and cloned into the vector pSilencer 2.1-U6-neo,which was named pSilencer 2.1-U6-neo-shRNA,were identified by restriction endonuclease digestion analysis and DNA sequencing.LNCaP cells were then transfected with these three pSilencer 2.1-U6-neo-shRNAs and the negative control pSilencer 2.1-U6-neo-NC.After G418 selection,the cells were selected and the interfering effect was detected by RT-PCR and Western blotting.The biological behaviours of the transfected LNCaP cells were also tested.RESULTS:Restriction endonuclease digestion analysis and DNA sequencing results all showed that the 3 target segments were cloned into pSilencer 2.1-U6-neo vector respectively.After transfected into LNCaP cells,the inhibitory ratio of PSMA mRNA was 33.15%,9.26% and 41.97% respectively,and that of PSMA protein was 26.26%,6.47%,40.69% respectively.The p-shRNA3 was chosen to test the cell growth and its invasive power in vitro.The results showed that after interfering,the invasiveness of LNCaP cells were enhanced.CONCLUSION:The vector-based shRNA on PSMA gene effectively knocks down the PSMA gene expression.The successful construction of PSMA shRNA makes it possible for further study of the interaction between PSMA and prostate cancer.
4.Analysis of gene structure and diversity of new alternative spliced variants of prostate specific membrane antigen
Kaiyuan CAO ; Na XIAO ; Lin XU ; Guangqing YUAN ; Shuqin DAI ; Xiaorong HUANG ; Xiaodong TIAN ; Shaopeng QIU
Chinese Journal of Pathophysiology 2000;0(12):-
AIM: To find out the gene structure and diversity of protate specific membrane antigen(PSMA) alternative spliced variants, and probe into the pathogenesis of prostate cancer.METHODS: 5'-RACE and 3'-RACE methods were used to amplify the 5' and 3'end of alternative spliced variant and then those viariants were sequenced for analyzing the gene stucture and diversity of PSMA alternative spliced variants of prostate cancer tissues.RESULTS: Four new alternative spliced variants of PSMA were discovered from prostate cancer tissues.Compared with reported PSMA alternative spliced variants,different insertions and deletions existed in different sites of those new variants.CONCLUSION: The discovery of the new variants confirms the diversity of PSMA spliced variants and provides the clues for seeking the target of diagnosis and therapy of prostate cancer.
5.An experimental study on rat model of parkinsonizm by gene therapy
Qunyuan XU ; Jingsheng TIAN ; Jinlu ZHANG ; Hui YANG ; Shaopeng ZHENG ; Yujun LIU
Chinese Medical Journal 1998;111(2):154-159
Objective To induce significant improvement of motor abnormalities and striatal dopamine (DA) levels in rat model of Parkinson's disease (PD), by intracerebral grafting of the genetically modified muscle cells expressing tyrosine hydroxylase (TH).Methods Primary myoblasts and myotubes from the rat were prepared by cell culture and a plasmid, pCMVTH,containing TH gene and a promoter of cytomegalovirus (CMV) was constructed by DNA recombination technique. The primary muscle cells were transfected with newly constructed pCMVTH DNA vector, by using lipofection. These genetically modified muscle cells were grafted into the caudate- putamen of 6-OHDA-lesioned rats, representing PD models. Before and after grafting, the rotational behaviour and the striatal levels of DA and its metabolities were tested at different postoperative survival times. In addition, the immunocytochemistry for showing TH activity was done both in vitro and in vivo.Results The newly constrcuted plasmid, pCMVTH was proved to contain TH gene and have correct direction of insertion. The cultured primary myoblasts and myotubes lipofected with pCMVTH were immunocytochemically shown to express TH activity in vitro. After grafting, these TH-expressing muscle cells showed to have a long-term survival cells in vivo and induced a marked decrease in abnormal locomotion and a increase in striatal DA levels for PD rat model.Conclusions In experimental gene therapy for PD, the pCMVTH is a useful vector for carrying TH gene. The lipofection is a practical technique for transferring a target gene into eukaryotes and primary cultured muscle cells should be a good vehicle for DNA transfer and intracerebral grafting.